Author

E. A. R. Garfinkle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Cotton· 1 shared A. M. Dorrance· 1 shared A. Obermayer· 1 shared A. Rudich· 1 shared B. Assaf· 1 shared B. Mundy-Bosse· 1 shared B. Zhang· 1 shared C. Capdevielle· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cotton

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia

C. Goda, R. Kulkarni, A. Rudich, M. Karunasiri, O. Balcioglu, Y. Al-Marrawi, E. Korn, S. Kanna, E. A. R. Garfinkle, B. Mundy-Bosse, B. Zhang, G. Marcucci, E. R. Mardis, R. Garzon, K. E. Miller, A. M. Dorrance

The paper identifies changes in the bone marrow microenvironment during preleukemic stages of AML, including an expanded CD55+ fibroblast population that supports preleukemic stem cells over normal HSCs.

bioRxiv · Sep 1, 2023Cancer Biology

CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to Navitoclax

M. Neault, C.-E. Lebert-Ghali, M. Fournier, C. Capdevielle, E. A. R. Garfinkle, A. Obermayer, A. Cotton, K. Boulay, C. Sawchyn, K. H. Nguyen, B. Assaf, F. E. Mercier, J.-S. Delisle, E. A. Drobetsky, L. Hulea, , F. A. Mallette

This study identifies GLIS2 as a driver of pediatric AMKL and shows its sensitivity to navitoclax, offering a potential therapeutic strategy.

Cell Reports · Sep 1, 2023Peer-reviewedCancer Biology